Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
105actual
Sites
14
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-24 | actual | When the study began enrolling |
| Primary completion | 2025-12-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis
- Crohn's Disease
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants who reported Serious Adverse Event
measured Up to 52 weeks
Percentage of participants who reported Serious Adverse Drug Reaction
measured Up to 52 weeks
Percentage of participants who reported unexpected (not reflected in the latest approved label) Adverse Events/Adverse Drug Reaction
measured Up to 52 weeks
Percentage of participants who reported known (labeled) Adverse Drug Reaction
measured Up to 52 weeks
Percentage of participants who reported non-serious Adverse Event/Adverse Drug Reaction
measured Up to 52 weeks
Percentage of participants who reported the events related to important identified risks/important potential risks/missing information
measured Up to 52 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed